S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern

AstraZeneca (AZN) Stock Price, News & Analysis

-0.52 (-0.75%)
(As of 04/12/2024 08:51 PM ET)
Today's Range
50-Day Range
52-Week Range
9.12 million shs
Average Volume
6.21 million shs
Market Capitalization
$213.71 billion
P/E Ratio
Dividend Yield
Price Target

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
16.1% Upside
$80.00 Price Target
Short Interest
0.25% of Shares Sold Short
Dividend Strength
Based on Four Factors
News Sentiment
0.78mentions of AstraZeneca in the last 14 days
Based on 25 Articles This Week
Insider Trading
Proj. Earnings Growth
From $4.02 to $4.66 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.31 out of 5 stars

Medical Sector

320th out of 928 stocks

Pharmaceutical Preparations Industry

138th out of 417 stocks

AZN stock logo

About AstraZeneca Stock (NASDAQ:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

AstraZeneca (NASDAQ:AZN) Shares Gap Up to $68.11
Traders Buy High Volume of AstraZeneca Put Options (NASDAQ:AZN)
The Next Bitcoin Millionaires
100,000 people became millionaires during Bitcoin’s last bull market. If you missed out… You have a second chance.
Spotlight on FTSE 100 stock AstraZeneca
The Next Bitcoin Millionaires
100,000 people became millionaires during Bitcoin’s last bull market. If you missed out… You have a second chance.
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 3/25 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
$5.96 billion
Pretax Margin


Sales & Book Value

Annual Sales
$45.81 billion
Cash Flow
$5.40 per share
Book Value
$12.63 per share


Outstanding Shares
Free Float
Market Cap
$213.71 billion

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained


Here are some ways that investors could benefit from investing in AstraZeneca:

  • AstraZeneca has a diverse portfolio of marketed products including Tagrisso, Imfinzi, Lynparza, and others, catering to various medical needs in cardiovascular, renal, metabolism, and oncology fields.
  • AstraZeneca's stock price has shown resilience, with a 1-year high of $76.56, indicating potential for growth.
  • The company has a strong financial standing with a market cap of $204.19 billion, showcasing stability and investor confidence.
  • AstraZeneca recently increased its dividend payout, offering investors a higher yield of 2.3%, which can be attractive for income-focused investors.
  • The company's focus on research and development, as seen in collaborations like with Neurimmune AG, indicates a commitment to innovation and future growth.


Investors should be bearish about investing in AstraZeneca for these reasons:

  • AstraZeneca's recent quarterly earnings results showed a slight miss on EPS, which might raise concerns about short-term performance.
  • The company's debt-to-equity ratio of 0.57 could be a red flag for investors cautious about leverage levels in the pharmaceutical industry.
  • While AstraZeneca has a diverse product portfolio, it also means exposure to various therapeutic areas, which could pose risks in case of regulatory challenges or market shifts.
  • The stock's 50-day moving average price being close to the 200-day moving average might indicate a lack of significant price momentum in the short term.
  • Investors should consider the competitive landscape in the pharmaceutical industry, as AstraZeneca faces competition from other major players in drug development and commercialization.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AZN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AZN, but not buy additional shares or sell existing shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price target for 2024?

6 brokers have issued twelve-month price objectives for AstraZeneca's shares. Their AZN share price targets range from $80.00 to $80.00. On average, they predict the company's share price to reach $80.00 in the next year. This suggests a possible upside of 16.1% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2024?

AstraZeneca's stock was trading at $67.35 at the start of the year. Since then, AZN stock has increased by 2.3% and is now trading at $68.93.
View the best growth stocks for 2024 here

Are investors shorting AstraZeneca?

AstraZeneca saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 7,660,000 shares, a drop of 26.9% from the March 15th total of 10,480,000 shares. Based on an average daily volume of 6,150,000 shares, the days-to-cover ratio is currently 1.2 days.
View AstraZeneca's Short Interest

When is AstraZeneca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our AZN earnings forecast

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) issued its quarterly earnings data on Thursday, February, 8th. The company reported $0.73 earnings per share for the quarter, missing analysts' consensus estimates of $0.74 by $0.01. The business earned $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a trailing twelve-month return on equity of 30.19% and a net margin of 13.00%. The firm's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period last year, the firm posted $0.69 earnings per share.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a Semi-Annual dividend on Thursday, February 8th. Shareholders of record on Friday, February 23rd will be given a dividend of $0.965 per share on Monday, March 25th. This represents a dividend yield of 2.3%. The ex-dividend date is Thursday, February 22nd. This is a boost from the stock's previous Semi-Annual dividend of $0.47.
Read our dividend analysis for AZN

Is AstraZeneca a good dividend stock?

AstraZeneca (NASDAQ:AZN) pays an annual dividend of $1.93 per share and currently has a dividend yield of 2.80%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 100.52%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AZN will have a dividend payout ratio of 41.42% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AZN.

When did AstraZeneca's stock split?

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

What other stocks do shareholders of AstraZeneca own?
Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Buckingham Capital Management Inc. (0.01%), Park National Corp OH (0.00%), IMC Chicago LLC (0.00%), Timber Creek Capital Management LLC (0.00%), Park Avenue Securities LLC (0.00%) and Perpetual Ltd (0.00%).
View institutional ownership trends

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AstraZeneca have any subsidiaries?
The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Inc., AstraZeneca Pharmaceuticals (Pty) Limited, AstraZeneca Pharmaceuticals Aktiebolag, AstraZeneca Pharmaceuticals Co. Limited, AstraZeneca Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, AstraZeneca Pharmaceuticals Limited, AstraZeneca Pharmaceuticals Pakistan (Private) Limited, AstraZeneca Pharmaceuticals Technologies (Beijing) Co. Ltd, AstraZeneca Produtos Farmaceuticos Lda, AstraZeneca Quest Limited, AstraZeneca Rho B.V., AstraZeneca S.A., AstraZeneca S.A. / N.V., AstraZeneca S.A. de C.V., AstraZeneca S.A.S., AstraZeneca Sdn Bhd, AstraZeneca Share Trust Limited, AstraZeneca Sigma B.V., AstraZeneca Singapore Pte Limited, AstraZeneca SpA, AstraZeneca Sweden Investments Limited, AstraZeneca Södertälje 2 AB, AstraZeneca Taiwan Limited, AstraZeneca Treasury B.V., AstraZeneca Treasury Limited, AstraZeneca Tunisie SaRL, AstraZeneca UK Limited, AstraZeneca US Investments Limited, AstraZeneca Ukraina LLC, AstraZeneca Venezuela S.A., AstraZeneca Vietnam Company Limited, AstraZeneca Zeta B.V, AstraZeneca d.o.o, AstraZeneca do Brasil Limitada, AstraZeneca Österreich GmbH, Atkemix Nine Inc., Atkemix Ten Inc., BMS Holdco Inc., Cambridge Antibody Technology, Cambridge Antibody Technology Group Limited, Centus Biotherapeutics Limited, Corpus Christi Holdings Inc., Definiens GmbH, Definiens Inc., Drimex LLC, Gotland Pharma S.A., Guangdong BeiKang Pharmaceutical Company Ltd, IPR Pharmaceuticals Inc., KuDOS Horsham Limited, KuDOS Pharmaceuticals Limited, KuDOS Pharmaceuticals Ltd, Laboratorio Beta S.A., Laboratorio Lailan S.A., Laboratorio Odin S.A., Laboratorio Tau S.A., MedImmune LLC, MedImmune Limited, MedImmune Pharma B.V, MedImmune U.K. Limited, MedImmune Ventures Inc, Montrose Chemical Corporation of California, Novastra Promoção e Comércio Farmacêutico Lda, Novastuart Produtos Farmaceuticos Lda, Novexel, Omthera Pharmaceuticals, Omthera Pharmaceuticals Inc., Optein Inc., P.T. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos .
Read More
This page (NASDAQ:AZN) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners